Across TCGA pan-cancer cohorts, GNAT2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GNAT2 data layer compared with 8 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher GNAT2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GNAT2 expression acts as an unfavorable survival marker.
COAD, SKCM, and ACC are the cancer types where GNAT2 Mutation most reproducibly stratifies survival.